Vanguard Capital Management
BIAF icon

Vanguard Capital Management’s bioAffinity Technologies BIAF Stock Holding History

Vanguard Capital Management’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.1K Hold
55,543
– – ﹤0.01% 3943
2026
Q1 		$213K Buy
+55,543
New +$89.7K ﹤0.01% 3790

Other funds holding BIAF

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Capital Management's BIAF Position: Q2 2026 in Review

Vanguard Capital Management held its bioAffinity Technologies (BIAF) position steady in Q2 2026 at 55,543 shares worth $45.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3943.

Vanguard Capital Management first reported a position in BIAF in Q1 2026 and has held it in 2 quarters since. The position peaked at $213K in Q1 2026. 19 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

  • Vanguard Capital Management held 55,543 shares of bioAffinity Technologies worth $45.1K as of Q2 2026.
  • Vanguard Capital Management left its bioAffinity Technologies share count unchanged in Q2 2026.
  • bioAffinity Technologies made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3943 holding.
  • Vanguard Capital Management first reported a position in bioAffinity Technologies in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's bioAffinity Technologies position peaked at $213K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.